BLACK DIAMOND THERAPEUTICS, INC. Proceeds from Stock Options Exercised
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Proceeds from Stock Options Exercised of $177.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2023-03-09
- BLACK DIAMOND THERAPEUTICS, INC. proceeds from stock options exercised for the quarter ending 2021-06-30 was $184.00K.
- BLACK DIAMOND THERAPEUTICS, INC. proceeds from stock options exercised for the quarter ending 2021-03-31 was $481.00K.
- BLACK DIAMOND THERAPEUTICS, INC. proceeds from stock options exercised for the quarter ending 2020-12-31 was $830.00K.
- BLACK DIAMOND THERAPEUTICS, INC. proceeds from stock options exercised for the quarter ending 2020-09-30 was $270.00K.
- BLACK DIAMOND THERAPEUTICS, INC. proceeds from stock options exercised for fiscal 2022 was $177.00K, a 75.72% decline from fiscal 2021.
- BLACK DIAMOND THERAPEUTICS, INC. proceeds from stock options exercised for fiscal 2021 was $729.00K, a 33.73% decline from fiscal 2020.
- BLACK DIAMOND THERAPEUTICS, INC. proceeds from stock options exercised for fiscal 2020 was $1.10M.
- BLACK DIAMOND THERAPEUTICS, INC. proceeds from stock options exercised for fiscal 2019 was $0.00.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2022-12-31 | $177.00K 10-K · filed 2023-03-09 | |||
| 2021-12-31 | $729.00K 10-K · filed 2023-03-09 | |||
| 2021-06-30 | $184.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $665.00K 10-Q · filed 2021-08-12 | $1.50M derived: sum of 3 quarters · filed 2022-03-17 | $1.76M derived: sum of 4 quarters · filed 2022-03-17 |
| 2021-03-31 | $481.00K 10-Q · filed 2021-05-07 | $1.31M derived: sum of 2 quarters · filed 2022-03-17 | $1.58M derived: sum of 3 quarters · filed 2022-03-17 | $1.58M derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-12-31 | $830.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $1.10M derived: sum of 2 quarters · filed 2022-03-17 | $1.10M derived: sum of 3 quarters · filed 2022-03-17 | $1.10M 10-K · filed 2022-03-17 |
| 2020-09-30 | $270.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $270.00K derived: sum of 2 quarters · filed 2021-08-12 | $270.00K 10-Q · filed 2020-11-10 | $270.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | $0.00 derived: sum of 3 quarters · filed 2021-08-12 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-07 | $0.00 derived: sum of 2 quarters · filed 2021-05-07 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $0.00 10-K · filed 2021-03-25 | ||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |